Why is reimbursement described as the dominant commercial challenge for digital therapeutics?

Even after achieving FDA clearance, a digital therapeutic generally has no established CPT or HCPCS code path guaranteeing payer reimbursement the way a traditional device or drug does, which means companies often must negotiate direct contracts with employers, health plans, or pharmacy benefit managers rather than relying on standard fee-for-service billing. Some digital therapeutics have failed commercially specifically because clinical evidence and FDA clearance did not translate into durable payer coverage, illustrating that regulatory success and commercial viability are separate hurdles that must both be cleared.

What clinical evidence does FDA expect to support a digital therapeutic claim?

FDA generally expects clinical evidence proportionate to the claim being made and the risk profile of the condition being addressed, which for many digital therapeutics has meant randomized controlled trials demonstrating a measurable clinical outcome, not just user engagement or satisfaction metrics. Because software can be updated frequently, manufacturers must also consider whether post-clearance modifications to the therapeutic content or algorithm require a new submission, similar to considerations that apply to other SaMD products.

What is the most common mistake digital therapeutics companies make before commercial launch?

Building and validating a clinically effective product without first confirming a viable reimbursement pathway or securing a B2B payer or employer contract is one of the most common and costly mistakes, since clinical validation alone does not create a revenue model in a market where CMS and commercial payer coverage for digital therapeutics remains inconsistent. Companies that engage payers and health system partners early, alongside the clinical development program, are generally better positioned to translate clearance into sustainable revenue.

All terms

Market SegmentsSoftware Lifecycle Strategic LandscapeDTx

Digital Therapeutics

Software-based interventions that prevent, manage, or treat disease.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

Digital therapeutics deliver evidence-based therapeutic interventions through software - mobile apps, browser-based programs, or VR - to treat conditions including substance-use disorder, insomnia, ADHD, and chronic pain. Products target conditions such as substance use, insomnia, ADHD and diabetes. Evidence typically comes from randomized controlled trials, and many are regulated as software as a medical device. Coverage remains limited in the US, while some European countries have dedicated payment routes.

What the regulation says

Digital therapeutics are not a standalone legal device category. In the US, oversight depends on intended use and risk: software intended to treat disease may qualify as a medical device, while some wellness functions are excluded. Section 3060 of the 21st Century Cures Act, enacted December 13, 2016, added these software exclusions in section 520(o) of the Federal Food, Drug, and Cosmetic Act. Depending on classification, a therapeutic product may require FDA clearance, De Novo authorization, or premarket approval. Evidence requirements are product-specific; randomized controlled trials are not universally mandatory. Applicable manufacturers must follow 21 CFR Part 820, revised by the Quality Management System Regulation published February 2, 2024, and effective February 2, 2026. In the EU, Regulation (EU) 2017/745, adopted April 5, 2017, has applied since May 26, 2021. Annex VIII, Rule 11 classifies software providing information for diagnostic or therapeutic decisions according to potential harm, generally in Class IIa or higher. Article 61 and Annex XIV govern clinical evaluation, with post-market surveillance obligations under Articles 83 to 86. For this MedTech segment, market authorization and reimbursement remain separate: regulatory compliance does not itself establish insurance coverage, and billing codes alone do not guarantee payment.

What this means in practice

FDA-cleared examples include Pear reSET (now defunct, illustrating reimbursement risk), Akili EndeavorRx (ADHD), and Somryst (insomnia). Reimbursement remains the dominant commercial challenge; CMS PFS DTx codes (HCPCS) are emerging.

Examples

A mobile application designed to deliver cognitive behavioral therapy (CBT) exercises for individuals struggling with chronic insomnia, aiming to improve sleep patterns and reduce reliance on pharmacological interventions.
A virtual reality program providing immersive therapeutic environments and guided exercises to help patients manage symptoms of anxiety disorders, building coping skills and promoting relaxation.
A smartphone-based program that offers interactive lessons and personalized coaching to support individuals in managing type 2 diabetes, focusing on diet, exercise, and medication adherence to improve glycemic control.

Common pitfalls

•Building a clinically validated product without a confirmed reimbursement path or B2B payer contract.

Frequently asked questions

A digital therapeutic that makes a specific claim to prevent, manage, or treat a disease or condition through software-delivered intervention is regulated as Software as a Medical Device and typically requires a 510(k) clearance or De Novo authorization, whereas a general wellness app that avoids disease-specific treatment claims can fall outside FDA's device jurisdiction entirely. This distinction matters commercially: a company that markets a digital therapeutic without appropriate clearance, or that oversteps its cleared indication for use, risks enforcement action even if the underlying software functionality is unchanged.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Market Segments

Wearable Medical Devices

Body-worn devices that continuously monitor physiological signals.

Software & AI

Software as a Medical Device(SaMD)

Software intended for medical purposes that performs without being part of a hardware device.

More in Market Segments

· Same category

Market Segments

Aesthetic & Energy-Based Devices

Lasers, RF, ultrasound, cryolipolysis, and IPL systems used for medical and cosmetic indications, body contouring, hair removal, skin tightening, vascular lesions.

Market Segments

AI Imaging Software

Software that analyzes medical images to triage, detect, or quantify disease.

Market Segments

Cardiac Rhythm Management(CRM)

Implantable and external devices that monitor and treat cardiac arrhythmias, pacemakers, ICDs, CRT devices, and insertable cardiac monitors.

Market Segments

Cardiovascular Devices

Devices for diagnosing, monitoring, or treating cardiovascular disease.

Cited by

Where this term appears across MedTech Terms.

Ecosystems (2)

Latest in MedTech

Sources

4 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 2Regulator guidance and consensus· 1Tier 4Trade press and expert commentary· 3

Link health: 4 verified· last checked 2026-06-20· added official documents checked 2026-11-01

Digital Therapeutics Alliance·1MedTech Dive·1AdvaMed·1U.S. Food and Drug Administration (FDA)·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Market Segments0 / 38

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Market Segments
Acronym: DTx
Sources: 4
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Software-based interventions that prevent, manage, or treat disease.

·FDA-cleared examples include Pear reSET (now defunct, illustrating reimbursement risk), Akili EndeavorRx (ADHD), and Somryst (insomnia).
·Reimbursement remains the dominant commercial challenge; CMS PFS DTx codes (HCPCS) are emerging.
·Products target conditions such as substance use, insomnia, ADHD and diabetes.

Remember this

Watch out: Building a clinically validated product without a confirmed reimbursement path or B2B payer contract.

Related terms

You may also need

Auto-suggested from Market Segments and shared keywords.

All Market Segments terms